Correction to: Nature Communications https://doi.org/10.1038/s41467-019-11782-w, published online 28 August 2019.
The original version of this Article contained an error in the Results section, which incorrectly read ‘Erb-sumIL2 did not make any change for tumor control when used after afatinib treatment. However, the administration of afatinib and the Erb-sumIL2 at the same time effectively control tumor growth and prevent tumor development after being rechallenged with a high dose of tumor cells (Fig. 5f).’ The correct version replaces ‘Erb-sumIL2’ with ‘Her-sumIL2’ in two instances. This has been corrected in both the PDF and HTML versions of the Article.
About this article
Cite this article
Sun, Z., Ren, Z., Yang, K. et al. Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nat Commun 11, 1716 (2020). https://doi.org/10.1038/s41467-020-15532-1